Postoperative and Preoperative Chemotherapy for Non-Small Cell Lung Cancer

Area of Science:

• Oncology
• Thoracic Surgery
• Medical Oncology

Background:

• Limited randomized trials exist for preoperative and postoperative adjuvant systemic therapy in non-small-cell lung cancer (NSCLC).
• Assessing the efficacy of current adjuvant therapies is crucial for improving patient outcomes.

Purpose of the Study:

• To review the current status of adjuvant therapy for NSCLC.
• To evaluate the effectiveness of preoperative and postoperative systemic treatments based on recent literature.

Main Methods:

• Systematic review of comparative trials and meta-analyses.
• Analysis of data on preoperative and postoperative adjuvant systemic therapy for NSCLC.

Main Results:

• Postoperative cisplatin-containing adjuvant therapy reduces the risk of death by 3% at two years and 5% at five years.
• Preoperative therapy achieved tumor clearance in about 15% of resected specimens, with two small trials indicating significant survival benefits.

Conclusions:

• Adjuvant systemic therapy, particularly with cisplatin-based regimens, offers a survival benefit for NSCLC patients.
• Further development of novel, more active regimens is needed to enhance the benefits observed in clinical trials for NSCLC adjuvant therapy.